FDA accepts Takeda’s NDA, grants review for budesonide oral suspension

Takeda Pharmaceutical announced the FDA accepted its new drug application and granted priority review fo r TAK-721, an investigational therapy budesonide oral suspension intended for the treatment of eosinophilic esophagitis.“EoE is a chronic, immune-mediated, inflammatory disease localized in the esophagus,” Karen Lasch, vice president, gastroenterology, U.S. Medical, told Healio Gastroenterology. “If left untreated, inflammation of EoE can worsen and narrow the esophagus over time, which can lead to food impaction that may necessitate urgent endoscopic intervention. Yet,Read More

Share on facebook
Share on twitter
Share on linkedin